May 26th, 2025 “EURETINA-Brief”© Issue No. 317
Dear EURETINA Members, A very warm welcome to the May 26th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
May 26th, 2025
Latest News
May 26th, 2025 “EURETINA-Brief”© Issue No. 317
Dear EURETINA Members, A very warm welcome to the May 26th, 2025 edition of EURETINA’s…
A research survey is the first to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs.
Researchers at the University College London, Institute of Ophthalmology, and Moorfields Eye Hospital, NHS Foundation…
Clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, may provide significant support for counselling and on-going clinical trials.
Clinical researchers at the Department of Ophthalmology and the Vision Centre of Excellence, Akron Children’s…
Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.
Ashvattha Therapeutics, based in Redwood City, California, have announced positive interim Phase 2 results for…